Therapeutic strategies for human amyloid diseases

Nature Reviews Drug Discovery

Volumn 1, Issue 4, 2002, Pages 267-275

  Sacchettini, James C ^a   Kelly, Jeffrey W ^b  

^a TEXAS A AND M UNIVERSITY   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID PRECURSOR PROTEIN; AMYLOID PROTEIN; FLUFENAMIC ACID; IMMUNOGLOBULIN F(AB) FRAGMENT; IMMUNOGLOBULIN LIGHT CHAIN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENOXAZINE DERIVATIVE; PREALBUMIN; PROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR; THYROXINE;

ALZHEIMER DISEASE; AMYLOID NEUROPATHY; BINDING AFFINITY; CONFORMATIONAL TRANSITION; DRUG BINDING SITE; DRUG DESIGN; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; DRUG TOLERABILITY; FAMILIAL AMYLOID POLYNEUROPATHY; GENE THERAPY; HUMAN; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN FOLDING; PROTEIN QUATERNARY STRUCTURE; PROTEINASE INHIBITION; REVIEW; RISK ASSESSMENT; RISK FACTOR; STRUCTURE ACTIVITY RELATION; TRANSGENIC ANIMAL; TREATMENT PLANNING; AMYLOIDOSIS; CHEMISTRY; DRUG ANTAGONISM; IMMUNIZATION; METABOLISM;

ALZHEIMER DISEASE; AMYLOID; AMYLOID NEUROPATHIES, FAMILIAL; AMYLOIDOSIS; HUMANS; IMMUNIZATION; RISK FACTORS;

EID: 0036527699     PISSN: 14741776     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrd769     Document Type: Review

References (105)

1. Kisilevsky, R. Biology of disease amyloidosis: a familiar problem in light of current pathogenic developments. Lab. Inv. 49, 381-390 (1983).
2. Pepys, M. B. in Immunological Diseases (ed. Samter, M.) 631-674 (Little, Brown and Co., Boston/Toronto, 1988).
3. Stevens, F. J. & Kisilevsky, R. Immunoglobulin light chains, glycosaminoglycans, and amyloid. Cell. Mol. Life Sci. 57, 441-449 (2000).
4. Sipe, J. D. Amyloidoses. Annu. Rev. Biochem. 61, 947-975 (1992).
5. Jacobson, D. R. & Buxbaum, J. N. Genetic aspects of amyloidosis. Adv. Human Genetics 20, 69-123 (1991).
6. Sipe, J. D. Amyloidosis. Crit. Rev. Clin. Lab. Sci. 31, 325-354 (1994).
7. Benson, M. D. & Wallace, M. R. in The Metabolic Basis of Inherited Disease (eds. Scriver, C. R., Beaudet, A. L., Sly, W. S. & Valle, D.) 2439 (McGraw Hill, New York, 1989).
8. Benson, M. D. Familial amyloidotic polyneuropathy. Trends Biochem. Sci. 12, 88-92 (1989).
9. Kelly, J. W. Alternative conformations of amyloidogenic proteins govern their behavior Curr. Opin. Struct. Biol. 6, 11-17 (1996).
10. Fink, A. L. Protein aggregation: folding aggregates, inclusion bodies and amyloid. Fold. Des. 3, R9-R23 (1998).
11. Sipe, J. D. Serum amyloid A. From fibril to function. Current status. Amyloid 7, 10-12 (2000).
12. Pepys, M. B. & Hawkins, P. N. Human lysozyme gene mutation causes hereditary systemic amyloidosis. Nature 362, 553-557 (1993).
13. Golde, T. E., Estus, S., Younkin, L. H., Selkoe, D. J. & Younkin, S. G. Processing of the amyloid protein precursor to potentially amyloidogenic derivatives. Science 255, 728-730 (1992).
14. Shoji, M. et al. Production of the Alzheimer amyloid β-protein by normal proteolytic processing. Science 258, 126-129 (1992).
15. Vassar, R. et al. β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science 286, 735-741 (1999).
16. Kimberly, W. T., Xia, W., Rahmati, T., Wolfe, M. S. & Selkoe, D. J. The transmembrane aspartates in presenilin 1 and 2 are obligatory for γ-secretase activity and amyloid β-protein generation. J. Biol. Chem. 275, 3173-3178 (2000).
17. 2+ stabilization. EMBO J. 20, 6277-6287 (2001).
18. Kelly, J. W. & Lansbury, P. T. J. A chemical approach to elucidate the mechanism of transthyretin and β-protein amyloid fibril formation. Amyloid: Int. J. Exp. Clin. Invest. 1, 186-205 (1994).
19. Moyer, B. D. & Balch, W. E. A new frontier in pharmacology: the endoplasmic reticulum as a regulated export pathway in health and disease. Emerging Therap. Targets 5, 165-176 (2001).
20. Kelly, J. W. Amyloid fibril formation and protein misassembly: a structural quest for insights into amyloid and prion diseases. Structure 5, 595-600 (1997).
21. Kelly, J. W. The environmental dependency of protein folding best explains prion and amyloid diseases. Proc. Natl Acad. Sci. USA 95, 930-932 (1998).
22. Westermark, P., Sletten, K., Johansson, B. & Cornwell, G. G. Fibril in senile systemic amyloidosis is derived from normal transthyretin. Proc. Natl Acad. Sci. USA 87, 2843-2845 (1990).
23. Saravia, M. J. M., Birken, S., Costa, P. & Goodman, D. S. Amyloid fibril protein in familial polyneuropathy, Portugese type: definition of molecular abnormality in transthyretin (prealbumin). J. Clin. Inv. 74, 104-119 (1984).
24. Selkoe, D. J. Alzheimer's disease: genotypes, phenotype and treatments. Science 275, 630-631 (1997).
25. Kiuru, S. Gelsolin-related familial amyloidosis, Finnish type (FAF), and its variants found worldwide. Amyloid 5, 55-66 (1998).
26. Hurle, M. R., Helms, L. R., Li, L., Chan, W. & Wetzel, R. A role for destabilizing amino acid replacements in light chain amyloidosis. Proc. Natl Acad. Sci. USA 91, 5446-5450 (1994).
27. Khurana, R. et al. Partially folded intermediates as critical precursors of light chain amyloid fibrils and amorphous aggregates. Biochemistry 40, 3525-3535 (2001).
28. Wanker, E. E. Protein aggregation in Huntington's and Parkinson's disease: implications for therapy. Mol. Med. Today 6, 387-391 (2000).
29. Wanker, E. E. Protein aggregation and pathogenesis of Huntington's disease: mechanisms and correlations. Biol. Chem. 381, 937-942 (2000).
30. Scherzinger, E. et al. Self-assembly of polyglutamine-containing huntingtin fragments into amyloid-like fibrils: implications for Huntington's disease pathology. Proc. Natl Acad. Sci. USA 96, 4604-4609 (1999).
31. Conway, K. A., Harper, J. D. & Lansbury, P. T. Jr. Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry 39, 2552-2563 (2000).
32. Goldberg, M. S. & Lansbury, P. T. Jr. Is there a cause-and-effect relationship between α-synuclein fibrillization and Parkinson's disease? Nature Cell Biol. 2, E115-E119 (2000).
33. Bruijn, L. I. et al. Aggregation and motor neuron toxicity of an ALS-linked SOD1 mutant independent from wild-type SOD1. Science 281, 1851-1854 (1998).
34. Caughey, B. Transmissible spongiform encephalopathies, amyloidoses and yeast prions: common threads? Nature Med. 6, 751-754 (2000).
35. Prusiner, S. B. & DeArmond, S. J. Prion protein amyloid and neurodegeneration. Amyloid 2, 39-65 (1995).
36. Hammarstrom, P., Schneider, F. & Kelly, J. W. Transsuppression of misfolding in an amyloid disease. Science 293, 2459-2461 (2001).
37. Selkoe, D. J. Amyloid β-protein and the genetics of Alzheimer's disease. J. Biol. Chem. 271, 18295-18298 (1996).
38. Schehr, R. S. Amyloid hypothesis of Alzheimer's rides high - for now. Nature Biotechnol. 15, 19-20 (1997).
39. White, J. T. & Kelly, J. W. Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro. Proc. Natl Acad. Sci. USA 98, 13019-13024 (2001).
40. Meyer, M. R. et al. APOE genotype predicts when - not whether - one is predisposed to develop Alzheimer disease. Nature Genet. 19, 321-322 (1998).
41. Roses, A. D. & Saunders, A. M. APOE is a major susceptibility gene for Alzheimer's disease. Curr. Opin. Biotechnol. 5, 663-667 (1994).
42. Hammarstrom, P., Jiang, X., Deechongkit, S. & Kelly, J. W. Anion shielding of electrostatic repulsions in transthyretin modulates stability and amyloidosis: insight into the chaotrope unfolding dichotomy. Biochemistry 40, 11453-11459 (2001).
43. Jimenez, J. L. et al. Cryo-electron microscopy structure of an SH3 amyloid fibril and model of the molecular packing. EMBO J. 18, 815-821 (1999).
44. Blake, C. & Serpell, L. Synchrotron X-ray studies suggest that the core of the transthyretin amyloid fibril is a continuous β-sheet helix. Structure 4, 989-998 (1996).
45. Serpell, L. C. et al. Examination of the structure of the transthyretin amyloid fibril by image reconstruction from electron micrographs. J. Mol. Biol. 254, 113-118 (1995).
46. Serpell, L. C. et al. The protofilament substructure of amyloid fibirls. J. Mol. Biol. 300, 1033-1039 (2000).
47. Sunde, M. et al. Common core structure of amyloid fibrils by synchrotron X-ray diffraction. J. Mol. Biol. 273, 729-739 (1997).
48. Lovat, L. B., Hohenester, E., Westermark, P., Wood, S. P. & Pepys, M. B. in Amyloid Amyloidosis 1998, Proc. 8th Int. Symp. Amyloidosis (eds Kyle, R. A. & Gertz, M. A.) 29-31 (Parthenon Publishing, New York, 1999).
49. Rydh, A. et al. Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation. Eur. J. Nucl. Med. 25, 709-713 (1998).
50. Klein, W. L., Krafft, G. A. & Finch, C. E. Targeting small Aβ oligomers: the solution to an Alzheimer's disease conundrum? Trends Neurosci. 24, 219-224 (2001).
51. Volles, M. J. et al. Vesicle permeabilization by protofibrillar α-synuclein: implications for the pathogenesis and treatment of Parkinson's disease. Biochemistry 40, 7812-7819 (2001).
52. Colon, W. & Kelly, J. W. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. Biochemistry 31, 8654-8660 (1992).
53. Lai, Z., Colon, W. & Kelly, J. W. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate which can self-assemble into amyloid. Biochemistry 35, 6470-6482 (1996).
54. McCutchen, S. F., Lai, Z., Miroy, G., Kelly, J. W. & Colon, W. Comparison of lethal and non-lethal transthyretin variants and their relationship to amyloid disease. Biochemistry 34, 13527-13536 (1995).
55. Jiang, X. et al. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. Biochemistry 40, 11442-11452 (2001).
56. Lashuel, H. A., Lai, Z. & Kelly, J. W. Characterization of the transthyretin acid denaturation pathways by analytical ultracentrifugation: implications for wild-type, V30M, and L55P amyloid fibril formation. Biochemistry 37, 17851-17864 (1998).
57. Liu, K., Cho, H. S., Lashuel, H. A., Kelly, J. W. & Wemmer, D. E. A glimpse of a possible amyloidogenic intermediate of transthyretin. Nature Struct. Biol. 7, 754-757 (2000).
58. Booth, D. R. et al. Instability, unfolding and aggregation of human lysosozyme variants underlying amyloid fibrillogenesis. Nature 385, 787-793 (1997).
59. Wetzel, R. Mutations and off-pathway aggregation of proteins. Trends Biotechnol. 12, 193-198 (1994).
60. Dobson, C. M. Protein misfolding, evolution and disease. Trends Biochem. Sci. 24, 329-332 (1999).
61. Miroy, G. J. et al. Inhibiting transthyretin amyloid fibril formation via protein stabilization. Proc. Natl Acad. Sci. USA 93, 15051-15056 (1996).
62. Peterson, S. A. et al. Inhibiting transthyretin conformational changes that lead to amyloid fibril formation. Proc. Natl Acad. Sci. USA 95, 12956-12960 (1998).
63. Klabunde, T. et al. Rational design of potent human transthyretin amyloid disease inhibitors. Nature Struct. Biol. 7, 312-321 (2000).
64. Petrassi, H. M., Klabunde, T., Sacchettini, J. & Kelly, J. W. Structure-based design of N-phenyl phenoxazine transthyretin amyloid fibril inhibitors. J. Am. Chem. Soc. 122, 2178-2192 (2000).
65. Oza, V. B., Petrassi, H. M., Purkey, H. E. & Kelly, J. W. Synthesis and evaluation of anthranilic acid-based transthyretin amyloid febril inhibitors, Bioorg. Med. Chem. Lett. 9, 1-6 (1999).
66. Baures, P. W., Peterson, S. A. & Kelly, J. W. Discovering transthyretin amyloid fibril inhibitors by limited screening. Bioorg. Med. Chem. 6, 1389-1401 (1998).
67. Baures, P. W., Oza, V. B., Peterson, S. A. & Kelly, J. W. Synthesis and evaluation of inhibitors of transthyretin amyloid formation based on the nonsteroidal anti-inflammatory drug flufenamic acid. Bioorg. Med. Chem. 7, 1339-1347 (1999).
68. Kelly, J. W. et al. Transthyretin quaternary and tertiary structural changes facilitate misassembly into amyloid. Adv. Protein Chem. 50, 161-181 (1997).
69. Krebs, M. R. H. et al. Formation and seeding of amyloid fibrils from wild-type hen lysozyme and a peptide fragment from the β-domain. J. Mol. Biol. 300, 541-549 (2000).
70. Chiti, F. et al. Designing conditions for in vitro formation of amyloid protofilaments and fibrils. Proc. Natl Acad. Sci. USA 96, 3590-3594 (1999).
71. Kirkitadze, M. D., Condron, M. M. & Teplow, D. B. Identification and characterization of key kinetic Intermediates in amyloid-β-protein fibrillogenesis. J. Mol. Biol. 312, 1103-1119 (2001).
72. Allsop, D. et al. Modulation of β-amyloid production and fibrillization. Biochem. Soc. Symp. 67, 1-14 (2001).
73. Howlett, D. R. Aβ Oligomerization: a therapeutic target for Alzheimer's disease. Curr. Med. Chem. Immunol. Endocr. Metab. Agents 1, 25-38 (2001).
74. Bohrmann, B. et al. Self-assembly of β-amyloid 42 is retarded by small molecular ligands at the stage of structural intermediates. J. Struct. Biol. 130, 232-246 (2000).
75. Findeis, M. A. & Molineaux, S. M. Design and testing of inhibitors of fibril formation. Methods Enzymol. 309, 476-488 (1999).
76. LeVine, H. & Scholten, J. D. Screening for pharmacologic inhibitors of amyloid fibril formation. Methods Enzymol. 309, 467-476 (1999).
77. Moore, C. L. & Wolfe, M. S. Inhibition of β-amyloid formation as a therapeutic strategy. Expert Opin. Ther. Pat. 9, 135-146 (1999).
78. Bandiera, T., Lansen, J., Post, C. & Varasi, M. Inhibitors of Aβ peptide aggregation as potential anti-Alzheimer agents. Curr. Med. Chem. 4, 159-170 (1997).
79. Glenner, G. G. et al. Creation of amyloid fibrils from Bence Jones proteins in vitro. Science 174, 712-714 (1971).
80. Shirahama, T. & Cohen, A. S. Intralysosomal formation of amyloid fibrils. Am. J. Pathol. 81, 101-116 (1975).
81. Shirahama, T. et al. Amyloid enhancing factor loaded macrophages in amyloid fibril formation. Lab. Inv. 62, 61-68 (1990).
82. Yamazaki, T., Koo, E. H. & Selkoe, D. J. Trafficking of cell-surface amyloid β-protein precursor II. Endocytosis, recycling, and lysosomal targeting detected by immunolocalization. J. Cell Sci. 109, 999-1008 (1996).
83. Yang, A. J., Chandswangbhuvana, D., Shu, T., Henschen, A. & Glabe, C. G. Intracellular accumulation of insoluble, newly synthesized Aβ n-42 in amyloid precursor protein-transfected cells that have been treated with Aβ 1-42. J. Biol. Chem. 274, 20650-20656 (1999).
84. Jiang, X., Buxbaum, J. N. & Kelly, J. W. The V122I cardiac variant of transthyretin increases the velocity of rate-limiting tetramer dissociation resulting in accelerated amyloidosis. Proc. Natl Acad. Sci. USA 98, 14943-14948 (2001).
85. Liu, K. et al. Deuterium-proton exchange on the native wild-type transthyretin tetramer identifies the stable core of the individual subunits and indicates mobility at the subunit interface. J. Mol. Biol. 303, 555-565 (2000).
86. Purkey H. E., Derrell, M. I. & Kelly, J. W. Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma. Proc. Natl Acad. Sci. USA 98, 5566-5571 (2001).
87. Oza, V. B. et al. Synthesis, structure and activity of diclofenac analogs as transthyretin amyloid fibril inhibitors. J. Med. Chem. 45, 321-332 (2002).
88. Suhr, O. B. Transplantation for amyloidosis. Rinsho Byori 48, 329-335 (2000).
89. Anderson, O. & Wallin, G. in Second International Symposium On Familial Amyloidotic Polyneuropathy and Other Transthyretin Belated Disorders 49 (Skelleftea, Sweden, 1992).
90. Wei, Y. et al. Disruption of protein-protein interactions: design of a synthetic receptor that blocks the binding of cytochrorne c to cytochrome c peroxidase. J. Chem. Soc. Chem. Commun. 1580-1581 (2001).
91. Schenk, D. et al. Immunization with amyloid-β attenuates Alzheimer disease-like pathology in the PDAPP mouse. Nature 400, 173-177 (1999).
92. Lee, V. M. Y. Aβ immunization: moving Aβ peptide from brain to blood. Proc. Natl Acad. Sci. USA 98, 8931-8932 (2001).
93. Coelho, T. et al. A strikingly benign evolution of FAP in an individual found to be a compound heterozygote for two TTR mutations: TTR Met30 and TTR Met119. J. Rheumatol. 20, 179 (1993).
94. Coelho, T. et al. Compound heterozygotes of transthyretin Met30 and transthyretin Met119 are protected from the devastating effects of familial amyloid polyneuropathy. Neuromusc. Disord. 6, 27 [AU:1 pge OK?] (1996).
95. Koepf, E. K. et al. Characterization of the structure and function of W to F WW domain variants: identification of a natively unnfolded protein that folds upon ligand binding. Biochemistry 38, 14338-14351 (1999).
96. Weggen, S. et al. A subset of NSAIDs lower amyloidogenic Aβ42 independently of cyclooxygenase activity. Nature 414, 212-216 (2001).
97. Kim, S.-H. et al. Furin mediates enhanced production of fibrillogenic ABri peptides in familial British dementia. Nature Neurosci. 2, 984-988 (1999).
98. Fan, J.-Q. Potential drug therapies for lysosomal storage disorders. Front. Biotechnol. Pharmacol. 2, 275-291 (2001).
99. Fan, J. -Q., Ishii, S., Asano, N. & Suzuki, Y. Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nature Med. 5, 112-115 (1999).
100. Perrier, V. et al. Mimicking dominant negative inhibition of prion replication through structure-based drug design. Proc. Natl Acad. Sci. USA 97, 6073-6078 (2000).
101. Kisislevsky, R. et al. Arresting amyloidosis in vivo using small molecule anionic sulfates or sulfonates: implications for Alzheimer's disease, Nature Med. 1, 143-148 (1995).
102. Ancsin, J. B. & Kisilevsky, R. The heparin/heparan sulfate-binding site on APO-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J. Biol. Chem. 274, 7172-7181 (1999).
103. Ancsin, J. B. & Kisilevsky, R. in Amyloid Amyloidosis 1998, Proc. 8th Int. Symp. Amyloidosis (eds Kyle, R. A. & Gertz, M. A.) 77-79 (Parthenon Publishing, New York 1999).
104. Morgan, D. et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature 408, 982-985 (2000).
105. Peretz, D. at al. Antibodies inhibit prion propagation and clear cell cultures of prion infectivity. Nature 412, 739-743 (2001).